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Abstract
Background: In women with duct carcinoma in-situ (DCIS) receiving breast conservation therapy
(BCT), in-breast recurrences are seen in approximately 10%, but cannot be accurately predicted
using clinical and histological criteria. We performed a case-control study to identify protein
markers of local recurrence risk in DCIS.
Methods: Women treated for DCIS with BCT, who later developed in-breast recurrence (cases)
were matched by age and year of treatment to women who remained free of recurrence (controls).
Results:  A total of 69 women were included in the study, 31 cases and 38 controls.
Immunohistochemical evaluation of DCIS tissue arrays was performed for estrogen receptor,
progesterone receptor, HER-2/neu, cyclin D1, p53, p21, cycloxygenase-2 (COX-2) and
peroxisome proliferator activated receptor γ (PPARγ). Two markers were significantly different
between cases and controls on univariate analysis: strong COX-2 expression was associated with
increased risk of recurrence, with 67% vs. 24% positivity in cases and controls p = 0.006; and
nuclear expression of PPARγ was associated with protection from recurrence with 4% vs. 27%
positivity in cases and controls, p = 0.024. In a multivariate model which included size, grade, COX-
2 and PPARγ positivity, we found COX-2 positivity to be a strong independent risk factor for
recurrence (OR 7.90, 95% CI 1.72–36.23)., whereas size and grade were of borderline significance.
PPARγ expression continued to demonstrate a protective trend, (OR 0.14, 95% CI 0.06–1.84).
Conclusion: Our findings suggest that COX-2 and PPARγ should be investigated further as
biologic markers to predict DCIS recurrence, particularly since they are also potential therapeutic
targets.
Background
With the widespread use of screening mammography, the
incidence of ductal carcinoma in-situ (DCIS) has
increased steadily[1], so that DCIS now accounts for up to
20% of newly diagnosed breast cancers[2]. Management
of localized DCIS has evolved from total mastectomy
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which is associated with an less than 2% ipsilateral recur-
rence risk to breast conservation therapy (BCT) and endo-
crine therapy where ipsilateral recurrence rates vary from
10%–40% [3,4]. Because of the increasing number of
women being diagnosed with DCIS, the identification of
those patients at high risk for a recurrence (invasive and
non-invasive) is of increasing importance. Morphological
factors such as grade and the presence of comedo-necrosis
have been used thus far to predict recurrence, but lack sen-
sitivity and are subject to variability of interpretation[5].
A number of molecular markers have been identified in
invasive breast cancers that have predictive as well as prog-
nostic value. Well known markers include the estrogen
receptor α (ER) and progesterone receptor (PR) which are
associated with improved outcomes and are predictive of
response to tamoxifen therapy. HER-2/neu is a tyrosine
kinase receptor related to the epidermal growth factor
receptor family. Overexpression of HER-2/neu in invasive
carcinoma is correlated with decreased relapse-free and
overall survival, and resistance to hormonal and cytotoxic
therapy[6]. In DCIS, HER-2/neu has been linked to
adverse clinicopathologic characteristics including higher
histological grade, comedo-necrosis and younger age.
Additionally, HER-2/neu is found more frequently in
DCIS associated with invasive cancer [7-10]. Cyclin D1,
p53, and p21, are all proteins involved in cell cycle regu-
lation and have prognostic value in invasive breast cancer
as well [11-14]. All of these markers have been identified
in DCIS recently, but their biologic significance is not
fully understood, and long-term data relating these mark-
ers to recurrence risk in DCIS are extremely scant[7,15-
17]. Two novel molecular markers are cycloxygenase-2
(COX-2) and peroxisome proliferator activated-receptor
gamma (PPARγ). COX-2 overexpression has been shown
to be up-regulated in many neoplastic and pre-neoplastic
lesions including invasive breast cancer and DCIS [18-20].
COX-2 is the inducible form of cyclooxygenase, the rate-
limiting enzyme for prostaglandin synthesis. PPARγs
appear to play a role in the regulation of many physio-
logic functions such as lipid metabolism, atherogenesis,
inflammation and cellular differentiation[21,22]. PPARγ
expression has been studied in invasive cancers but not in
DCIS thus far.
We have conducted an exploratory study to identify those
molecular markers associated with increased or decreased
ipsilateral in-breast recurrence after diagnosis of DCIS, in
a population with long term follow-up; we opted for a
case-control design because of the relative rarity of DCIS
recurrence.
Methods
Following IRB approval of the study, women diagnosed
with DCIS and treated with breast conservation, who sub-
sequently developed ipsilateral recurrence of ductal carci-
noma, either invasive or non-invasive, (cases) were
identified from the Northwestern Memorial Hospital
tumor registry and the Lynn Sage Breast Center database
from 1992–2002. We have used the term "breast conserv-
ing therapy" to include all women treated without mastec-
tomy; of these 60% also received breast radiotherapy,
which was not a standard component of BCT for DCIS
during the earlier part of the study. Similarly, tamoxifen
therapy was introduced into the treatment of DCIS over
this time period, and just 32% of our study subjects were
treated with tamoxifen. Only women who had their orig-
inal surgery at Northwestern Memorial Hospital were
included, because the tissue blocks at primary diagnosis
were needed to create tissue microarrays. The recurrences
were in the same region of the breast as the original DCIS,
and were characterized as "local recurrences" by the treat-
ing physicians. These cases were age-matched (within two
years) to a set of control subjects diagnosed with DCIS
and treated with breast conservation in the same calendar
year, who did not recur over the same time period (con-
trols). Matching for tumor size and grade was not possible
because of the relative scarcity of younger women with
DCIS and the limited number of women undergoing
breast conservation early in study period. Clinical infor-
mation recorded on chart review included age, race, age of
menarche, first live birth, time to recurrence, type of sur-
gery, the type of recurrence (DCIS or invasive cancer), use
of adjuvant therapy in the form of radiation or endocrine
therapy (Tamoxifen) and current follow-up status. Hema-
toxylin and eosin stained paraffin sections of the case-con-
trol groups were evaluated for size of DCIS and margin
status. The grade of DCIS was classified according to the
criteria of Page and Lagios [23]; since grading was not uni-
formly practiced during the early part of the study period,
and complete sets of slides were not available on every
patient, we elected to review the grade on the TMA core
samples for all study subjects. Free margins were defined
as a tumor clearance of 2 mm or greater on review.
Tissue microarray preparation and immunohistochemical 
analysis
Areas of morphologically representative, non-necrotic
sites in the tumor sections were chosen to prepare tissue
microarrays (TMA). From each tumor block, two 1.5-mm
cores were obtained using tissue arraying instrument
(Beecher Instruments; Silver Spring, MD) TMA blocks
were prepared using previously described protocol by
Kononen et al[24]. Each TMA block consisted of 8–17
cores per block. The coordinates and clinicopathologic
data were documented to identify the cores. Sections of 4-
μm thickness were used for immunohistochemical analy-
sis of markers with H&E-stained sections as morphologi-
cal references for each core. Approximately 30% of the
DCIS lesions were not represented on the TMA sectionsBMC Cancer 2008, 8:36 http://www.biomedcentral.com/1471-2407/8/36
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either because no DCIS cells were present in a section or
complete absence of a core secondary to tissue exhaustion
in the block. We attributed this to the nature of many of
the samples that contained small and/or scattered areas of
DCIS in the donor blocks. Because of this sample loss,
there are different samples sizes for each molecular
marker.
Molecular markers that have been identified in invasive
cancer as having predictive and prognostic value were
chosen for our study. These included estrogen receptor
alpha (ER-α), progesterone receptor (PR), HER-2/neu,
COX-2, PPARγ, cyclin D1, p53, and p21. For all of the
markers tested, we used standardized automated immu-
nohistochemical techniques (DAKO Autostainer) along
with heat induced antigen retrieval. The clones, dilutions
and manufacturers of the primary antibodies used for the
study are shown in Table 1.
Immunohistochemical scoring of cases was performed by
a breast pathologist (LKD) with additional review of
equivocal cases by a second pathologist (EL), and final
scoring by consensus. All scoring was blinded to patient
information, including case-control status. Scoring of
each marker was also blinded to the scoring for other
markers. Specific scoring systems were used for the vari-
ous sets of markers studied. Nuclear markers were consid-
ered positive when the fraction of stained nuclei was ≥
10% (ER-α, PR, p53, p21 and cyclin D1), regardless of the
intensity of the immunostain. HER-2/neu cores were
scored using a standard 0,1+, 2+ and 3+ membrane stain-
ing intensity scale; 3+ staining of > 10% cells was required
for positivity. COX-2 staining was scored using a system
similar to that described for COX-2 evaluation of invasive
breast cancer on TMA sections[25]. A three-tiered system
was utilized for staining intensity: negative, weak and
strong staining. Staining was considered positive if strong
cytoplasmic granular staining in > 10% of tumor cells was
present.
PPARγ staining was evaluated using a descriptive scoring
system taking into account the possibility of nuclear and
cytoplasmic staining patterns as previously described for
PPARγ staining in invasive breast carcinoma[26]. We clas-
sified cases as: cytoplasmic staining only, combined
nuclear and cytoplasmic staining and nuclear staining
only. Staining was considered positive if > 10% of tumor
cells displayed nuclear staining. Examples of DCIS show-
ing positivity for COX-2 and PPARγ are shown in Figures
1 and 2.
If two cores from the same patient were found to have dis-
cordant IHC results, i.e. one core was read as positive and
one as negative, or one core was scored as +3 and the sec-
ond core as +2, the positive result or the higher IHC score
was used for the analysis.
Statistical analysis
All markers were compared between cases and controls.
Since there were only eight invasive recurrences, we did
not attempt subset analyses of invasive versus non-inva-
sive recurrences. The term "recurrence" is therefore used to
encompass both invasive and non-invasive recurrence.
Each marker was classified as positive or negative based
on the criteria described above and in Table 1. After
descriptive statistical analyses, to assess the distribution of
each marker, and to check for outliers, a univariate analy-
sis was performed for each marker. Continuous and ordi-
nal measures were compared between cases and controls
using the paired t-test or the Wilcoxon signed rank test.
Dichotomous measures were compared using the chi-
square test. After univariate analysis, multivariate analysis
using conditional logistic regression (for matched sam-
ples) was used to identify the markers that demonstrated
odds ratios that were different from unity, using a thresh-
old p value of 0.1. All p values are two-tailed. The associ-
ations between positivity of various markers was explored
using Spearman's rank correlation.
Table 1: Antibodies and scoring system used for analysis
Antibody* Dilution Clone Method of scoring
ER-α 1:300 1D5 > 10% positive cells – positive, < 10%- negative
PR 1:400 PgR636 > 10% positive cells – positive, < 10%- negative
HER-2/neu 1:200 ** Scored as +1, +2 and +3, +3- positive, +1/+2 -negative
COX-2 1:100 CX229 Strong positive, weak positive, negative
PPARγ 1:50 E8 Nuclear, cytoplasmic, nuclear+cytoplasmic, negative
P53 1:200 DO-7 > 10% positive cells – positive, < 10% -negative
P21 1:50 SX118 > 10% positive cells – positive, < 10% -negative
Cyclin D1 1:300 DCS-6 > 10% positive cells – positive, < 10% -negative
*All antibodies were purchased from Dako Cytomation except COX-2 (Cayman Chemicals), PPARγ (Santa Cruz Biotechnologies), Cyclin E (Lab 
Vision Corporation) and CXCR4 (R&D Systems)
** DAKO polyclonal antibody A0485.BMC Cancer 2008, 8:36 http://www.biomedcentral.com/1471-2407/8/36
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Results
There were a total of 69 women included in the analysis;
31 cases (those women who developed an ipsilateral non-
invasive or invasive in-breast recurrence during the study
period, 1992–2002) and 38 controls (those women who
did not recur). The clinical characteristics of the study
population are shown in Table 2. The mean age for the
cases was 53.3 years and the mean age for the controls was
53.7 years. Ages ranged from 35 to 80 years. The mean
tumor size was 17.7 mm in the cases and 11.9 mm in the
controls. This difference was of borderline statistical sig-
nificance (p = 0.062). The majority of the patients in our
study group had DCIS lesions that were classified as histo-
logical Grade 2. More Grade 3 tumors were found in the
cases in comparison to controls; this difference too, was of
borderline statistical significance (p = 0.069). The major-
ity of women (approximately 90% in each group) had free
resection margins defined as 2 mm or greater documented
on the review of pathologic material performed for this
study. Margins of resection were involved with DCIS in
three controls and two cases, and were unknown in five
controls and one case. All radiotherapy was to the whole
breast. The proportion of patients receiving radiation ther-
apy was similar between cases (65%) and controls (61%)
and was not associated with recurrence risk (OR 1.2, 95%
CI 0.45–3.3) The use of adjuvant tamoxifen therapy was
equally infrequent between cases (32%) and controls
(32%), and was not associated with a decreased risk of
recurrence (OR0.99, 95% CI 0.64–1.51). Many of these
patients were treated prior to 2003, when ER testing was
not routine clinical practice at our institution. Tamoxifen
recommendations were not based on ER status of DCIS
prior to this date. When we examined the tamoxifen use
based on ER data generated on the TMAs produced for this
study, we found no differences in the proportion of ER
positive cases and controls who received tamoxifen ther-
apy (7/12 ER positive controls vs. 6/10 ER positive cases).
The mean time to recurrence in the cases was 38.5 months
(range 6–114 months). Eight cases (26%) experienced an
invasive ipsilateral recurrence and 23 cases (74%) had a
DCIS recurrence.
Our target retention rate in successive TMA sections was
70% of cores, and was not related to the overall size of the
DCIS lesions. There were 18 subjects (4 cases and 14 con-
trols) with target loss of both cores for at least one marker.
The mean size of the DCIS in these 18 women was 13.8
mm; the mean tumor size among lesions with target loss
was similar to those in which target tissue was retained
(17.67 vs. 17.72 mm in cases and 11.4 vs. 11.9 in con-
trols). Thus the loss of DCIS target was not attributable to
tumor size (p = 0.7). However, there was a trend towards
better retention of DCIS target with increasing grade. Of
18 Grade 1 lesions, target tissue was lost for at least one
marker in seven subjects (39%); among Grade 2 lesions
the corresponding proportion was 10/34 (29%), and
among Grade 3 lesions it was 1/17 (6%) (p = 0.070).
A number of biomarkers were initially evaluated as part of
our study. These biomarkers were chosen because of their
role in cell cycle regulation, proliferation, differentiation,
and apoptosis as well as evidence of prognostic ability in
invasive breast cancer. Individually these were found not
to be associated positively or negatively with any ipsilat-
eral recurrence (see Table 3), with the exception of COX-
Nuclear positivity for PPAR gamma in tissue microarray sec- tion of ductal carcinoma in-situ (DCIS) of the breast Figure 2
Nuclear positivity for PPAR gamma in tissue microarray sec-
tion of ductal carcinoma in-situ (DCIS) of the breast. Original 
magnification, ×400.
Figure 2
Strong COX-2 positivity on immunohistochemical staining in  tissue microarray section of ductal carcinoma in-situ (DCIS)  of the breast Figure 1
Strong COX-2 positivity on immunohistochemical staining in 
tissue microarray section of ductal carcinoma in-situ (DCIS) 
of the breast. Original magnification, ×400.
Figure 1BMC Cancer 2008, 8:36 http://www.biomedcentral.com/1471-2407/8/36
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2 and PPARγ positivity. The results for COX-2 and PPARγ
staining are presented in more detail below.
COX-2 Expression in DCIS
COX-2 expression could be evaluated in 59 samples; cores
from 10 samples (6 controls and four cases) were lost in
the TMAs. Of the 59 women with evaluable COX-2 stain-
ing, 45.7% had strong COX-2 expression. (Fig 1) There
was a significant difference in the proportion of cases that
expressed COX-2 by immunohistochemistry compared to
controls. (P = 0.006). Strong cytoplasmic COX-2 staining
was found to be associated with ipsilateral breast recur-
rence after breast-conserving treatment of DCIS. The odds
ratio (OR) on univariate analysis was 5.11 (95% CI 1.7–
15.5). We did not see a significant association between
strong COX-2 expression and histological grade of the
lesions, although the majority of Grade 1 lesions were
COX-2 negative (9/13, 69%). In the 10 samples where
COX-2 expression data were missing due to core loss, the
mean size of the DCIS lesions was smaller in the 4 cases
(7.25 mm, range 4–15 mm) than in the six controls (12.8
mm, range 2–25 mm).
Although this study lacked the statistical power to exam-
ine non-invasive and invasive recurrences separately, it is
noteworthy that four of the six cases with invasive recur-
rences were COX-2 positive. (One of the six was negative
and the other case was lost during processing). There was
no difference in COX-2 expression between younger
women and older women (using an age threshold of 50
years). Although other studies have indicated that HER-2/
neu over-expression is associated with DCIS recur-
rence[7], we did not find an association between HER-2/
neu over-expression and ipsilateral DCIS recurrence (p =
0.538). The expression of HER-2/neu and COX-2 was con-
cordant in 29/52 lesions that could be assessed for both
proteins (12 lesions were positive for both and 17 lesions
were negative for both). Dual negativity for COX-2 and
HER-2/neu was significantly associated with control sta-
tus (17 of 27 controls were dual negative, p = 0.024). Dual
positivity for COX-2 and HER-2/neu was not associated
with an increase in recurrence risk over COX-2 positivity
alone.
PPARγ Expression in DCIS
PPARγ positivity was evaluable in 51 women (25 cases
and 26 controls); nuclear staining was seen by immuno-
histochemistry in eight of 51 women (15.6%). This
includes patients who have nuclear staining alone or
nuclear and cytoplasmic staining (Fig 2). Only one of the
cases expressed nuclear PPARγ gamma, compared to seven
of 26 (27%) of controls. This difference was statistically
Table 3: Proportion of Cases and Controls with Positive Staining of DCIS Lesions for Markers of Interest
Molecular Markers Cases N (% positive) Controls N (% positive) Total (N) P value
ER 20 (77%) 22 (79%) 54 0.884
PR 21 (81%) 20 (71%) 54 0.422
HER-2/neu 14 (56%) 18 (64%) 53 0.538
P53 17 (74%) 19 (63%) 53 0.413
Cyclin D1 16 (64%) 16 (59%) 52 0.726
COX-2 18 (67%) 9 (29%) 59 0.006
PPARγ 1 (4%) 7 (27%) 51 0.024
P21 9 (37%) 7 (23%) 54 0.257
Table 2: Clinical and Pathologic Characteristics of DCIS Lesions in Study Subjects.
Cases N (%) Controls N (%) P value
Number of Subjects 31 38
Mean age (range) 51 (36–77) 50.5 (35–79)
Mean size in mm (range) 17.7 (4–73) 11.9 (2–31) 0.06*
DCIS grade:
Grade 1 5 (16.) 13 (34)
Grade 2 16 (52.) 18 (47)
Grade 3 10 (33) 7 (18) 0.07
Free margins (2 mm or greater) 28 (90) 30 (79) 0.72
Invasive recurrence 8 (26) -
DCIS recurrence 23 (74) -
Tamoxifen Use 10 (32) 12 (32) 0.66
Radiation Therapy 20 (65) 23 (61) 0.71
*T test, two-tailed p value
~ Margin status missing in 1 case and 5 controlsBMC Cancer 2008, 8:36 http://www.biomedcentral.com/1471-2407/8/36
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significant (p = 0.024). Interestingly, expression was lim-
ited to grade 2 and 3 DCIS with a highly significant inter-
action (p < 0.00001) between PPARγ and grade. The odds
ratio for recurrence was 0.11 (95% CI 0.012–1.00, p =
0.050) indicating a protective effect of nuclear PPARγ
against recurrence. There was no association between age
or HER-2/neu status and PPARγ expression. The protective
effect of PPARγ positivity was not changed in multivariate
modeling with tamoxifen, radiation therapy, tumor size,
estrogen receptor status and margin status. Among the
group where PPARγ data was missing as a result of
processing-related core loss, 12 samples were from con-
trols and 6 were from cases. Similar to the core loss pattern
seen with COX-2 staining, the tumor size in case lesions
with core loss was similar to that of control lesions with
core loss during PPARγ staining (6.8 mm, range 4–20 mm
in cases and 8.7 mm, range 2–20 mm in controls).
Results of combined analysis of Grade, COX-2 and PPARγ 
expression
We performed a multivariate analysis including the four
parameters which were significant at a p value of 0.1 or
lower (size, grade COX-2, PPARγ). COX-2 expression con-
tinued to be significantly associated with increased risk of
any ipsilateral in-breast recurrence, with an OR of 7.89
(95%CI 1.7–36.2). Tumor size remained positively, but
not significantly, associated with recurrence risk, with a
5% increase in risk for each mm increase in size (OR 1.05,
95% CI 0.97–1.1). The association of grade and ipsilateral
breast recurrence also remains statistically non-signifi-
cant, although the point estimate remained elevated, with
an OR of 1.58 (95% CI 0.5–4.9). In this multivariate
model, PPARγ expression remained negatively associated
with recurrence, with an OR of 0.17 but this was no longer
statistically significant (95% CI 0.02–1.8), (see Table 4).
Associations between markers
Relationships between the markers tested were explored
to look for consistency with known correlations, and to
identify additional associations which may be of biologi-
cal interest. These are shown in Table 5. COX-2 expression
and PPARγ expression in DCIS had a significant inverse
relationship, consistent with their opposite effects on
recurrence risk As expected, estrogen and progesterone
receptor positivity was highly and significantly correlated
(p < .0001), and progesterone receptor expression dis-
played a significant inverse relation with HER-2/neu pos-
itivity. The expected association between ER positivity and
Cyclin D1 was also observed [27,28], as was the positive
association between ER and p21 positivity. [16]. There
were weaker, although significant associations of p53 pos-
itivity with ER and cyclin D1 positivity, which are of
uncertain significance. Also noted was a strong and signif-
icant association between p21 and cyclin D1 positivity,
consistent with the suggestion that cyclin D1 expression
may be indirectly induced as a result of the accumulation
of wild-type p53 through p21 [16].
Discussion
Our results show that strong cytoplasmic COX-2 expres-
sion by immunohistochemistry is an independent predic-
tor of increased risk of ipsilateral in-breast recurrence.
Furthermore, even though the number of cases was small,
COX-2 expression appears to be associated with the devel-
opment invasive recurrence. The risk of recurrence associ-
ated with strong COX-2 positivity was independent of
tumor size, margin status, estrogen receptor positivity, use
of radiotherapy, and tamoxifen use. This report is corrob-
orated by a recent study, where the COX-2 positivity rate
in recurrent DCIS (62%) was very similar to ours (67%)
although COX-2 positivity by itself was not a statistically
significant predictor of recurrence in that study (p =
0.08)[29]. Other studies have shown an association
between COX-2 overexpression and an aggressive pheno-
type in invasive breast cancer[30,31] and several studies
suggest that COX-2 expression is associated with a worse
prognosis [32-34]. Together, these findings are exciting
for several reasons. COX-2 could potentially be incorpo-
rated into the clinic as a prognostic marker for ipsilateral
in-breast recurrence, especially invasive recurrence. Excel-
lent antibodies exist for COX-2 staining, it is easily repro-
ducible and scoring is straightforward. Prostaglandin E2,
the primary product of COX-2, induces inflammation and
can act as a mediator in signal transduction pathways that
modulate cellular adhesion and cell growth[35,36]. COX-
2 inhibitors were being actively investigated in clinical tri-
als for treatment of breast cancer and as chemopreventive
agents in high risk women[37], until toxicity concerns
interrupted many of these trials. Our results provide
added incentive to develop and test new agents to target
this pathway, known to be of importance in several epi-
thelial malignancies. We found that roughly half of the ER
positive DCIS lesions in our study overexpressed COX-2
protein, the rate limiting enzyme in prostaglandin synthe-
Table 4: DCIS recurrence risk related to histologic grade, COX-
2 positivity, and PPARγ positivity.
Univariate Analysis OR 95% CI p value
Size 1.05 0.99–1.10 0.081
Grade 1.92 0.95–3.87 0.069
COX-2 5.11 1.7–15.5 0.004
PPARγ 0.11 0.01–1.0 0.05
Multivariate Analysis
Size 1.05 0.97–1.15 0.237
Grade 1.58 0.50–4.93 0.434
COX-2 7.90 1.72–36.23 0.008
PPARγ 0.17 0.06–1.84 0.144BMC Cancer 2008, 8:36 http://www.biomedcentral.com/1471-2407/8/36
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sis. The use of aromatase inhibitors may be particularly
useful in these patients given the evidence that aromatase
expression is upregulated by prostaglandins, and aro-
matase mRNA expression is suppressed by COX-2 inhibi-
tors[38].
Several studies have identified younger age as a factor that
increases the risk of recurrence after BCT for DCIS[39,40];
we attempted to determine if this was explained by higher
COX-2 expression in younger women, but did not find an
association between age and COX-2 expression, in agree-
ment with previous studies[31]. We also examined the
association between COX-2 expression and HER-2/neu
over-expression. In invasive cancers, COX-2 expression is
more often found in those patients who are HER-2/neu
positive[41], but in a separate study of women with node
negative breast cancer, the prognostic value of COX-2 pos-
itivity was independent of HER-2/neu amplification[42].
We found a similar pattern in DCIS, in agreement with a
recent study[18]; however, we did not note an increased
risk of recurrence with co-expression of HER-2/neu and
COX-2 over patients who expressed COX-2 alone.
As far as we know this is the first report of PPARγ expres-
sion in human DCIS, although one previous study does
show a favorable effect of PPARγ positivity on prognosis
in women with invasive ductal cancer[26]. PPARγs are
members of the nuclear receptor super-family that
includes steroid, retinoid and thyroid hormone recep-
tors[43,44]. There are three isoforms: PPARα, PPARδ and
PPARγ, which are encoded by different genes and demon-
strate organ-specific variation in expression throughout
the body. Two forms of PPARγ (PPARγ1and PPARγ2) have
been identified. PPARγ2 is expressed only in fat cells;
PPARγ1 has been found to be expressed in normal breast
epithelium and breast cancers[45]. PPARγ as well as the
other PPARs hetrodimerize with the retinoid X receptors
(RXRs) and then bind to the peroxisome proliferator
response elements (PPREs) in the promoter regions of tar-
get genes. Ligand binding causes a conformational change
in the heterodimer that causes the co-repressor protein to
dissociate allowing for activation of gene transcription
that is responsible for cell cycle modulation, cellular dif-
ferentiation, decreased proliferation, and inhibition of
angiogenesis[21,22]. Natural low affinity ligands of
PPARγ include fatty acids and ecosanoids such as prostag-
landin J2 (PGJ2). Thiazolidinediones, an FDA approved
class of anti-diabetic drugs, are highly selective activating
ligands for PPARγ at doses used to treat diabetes[46,47].
Our study suggests that the presence of PPARγ in DCIS
may be protective against ipsilateral recurrence particu-
larly in Grade 2 and 3 lesions. However, because of the
higher rate of Grade 1 core loss during processing, PPARγ
positivity was determined in only 9 of the 18 grade 1 DCIS
lesions in the study. All nine of these grade 1 DCIS lesions
were negative for PPARγ; six of these tumors were in the
control group. It is possible therefore (and even likely,
given the association of PPARγ expression with Grade 1 in
invasive breast cancer[48]) that PPARγ expression in
Grade 1 DCIS is more frequent than what we see in our
population, but this awaits a larger study, and may require
the use of whole sections rather than TMAs, As with COX-
2 positivity, there was no association of PPARγ positivity
with age or HER-2 status, although it has been reported in
one study that PPARγ may inhibit HER-2 pathways in cell
culture models[49].
Previous studies have shown that PPARγ ligands were able
to cause terminal differentiation of liposarcoma[50]. In
breast cancer, numerous cell culture models have shown
PPARγ ligand activation induces differentiation and
inhibits proliferation[45,51]. Only one study to date has
looked at PPARγ ligands in human breast cancer. It was
undertaken in a group of women with refractory breast
cancer. No response was seen after treatment[46]; how-
ever, the authors did not examine tumors for PPARγ
expression, and if this is associated with a favorable phe-
notype, it is possible that these women with refractory
advanced disease had largely PPARγ negative tumors.
Table 5: Correlations between biomarker positivity for all lesions (case and control)
PPARγ COX-2 ER PR Cyclin-D HER2/neu P53
PPARγ
COX2 -.310*
ER .096 -.035
PR -.062 -.0667 .673***
Cyclin D .092 -.104 .318** .497***
HER-2/neu -.102 .183 -.164 -.389** -.089
P53 .010 .142 .206* .163 .233* .194
P21 -.006 -.036 .256* .414*** .488*** .123 .391***
Spearman correlations
.* less than 0.05 ** less than 0.005 ***less than .0005BMC Cancer 2008, 8:36 http://www.biomedcentral.com/1471-2407/8/36
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It is not surprising to find an inverse relationship between
expression of COX-2 and PPARγ, given their respective
biologic functions. In invasive breast cancer, PPARγ
mRNA is significantly decreased compared to normal tis-
sues[52,53] and COX-2 levels have been shown to be
upregulated in breast cancer in multiple studies[54,55].
This inverse relationship has been demonstrated previ-
ously in invasive carcinoma[52]. To our knowledge this is
the first time this relationship has been shown in DCIS.
Evidence for a coordinated relationship between COX-2
and PPARγ comes from studies that showing activation of
PPARγ suppresses transcriptional activation of COX-2 in
cell culture models[41]. Another theory for this inverse
relationship has to do with one of the products of consti-
tutive Cyclooxygenase-1, PGJ2, a PPARγ ligand, which is
downregulated in a paracrine fashion by PGE2, the major
product of inducible COX-2[56]. We devised a scoring
system, combining COX-2 and PPARγ status with size and
grade, two important prognostic factors in DCIS.
The limitations of our study include the relatively small
size, which was related to the need for tissue from the time
of the initial diagnosis, limiting eligibility to patients hav-
ing their initial surgery at Northwestern Memorial Hospi-
tal. Tumor size and grade, both of which have been found
to predict recurrence risk in other studies, demonstrated a
similar trend in this study, but were of borderline signifi-
cance, most likely related to the small size of the study. We
found that 25% of our patients had grade 3 DCIS, whereas
the proportion of grade 3 DCIS in published series ranges
from 28% to 50% [57-59] or higher [29]. Since grading of
DCIS was not uniformly practiced at NMH over the course
of the study, we reviewed grade on all study subjects,
based on the TMA core samples. It is possible that the
evaluation of DCIS grade on the TMA cores accounted for
the high number of grade 2 cases, since heterogeneous
distribution of necrosis in the DCIS lesion may not have
been captured in the TMA cores, leading to the misclassi-
fication of some grade 3 lesions. This may also have
reduced our power to detect the effect of grade on recur-
rence risk, and the high proportion of HER-2/nue positiv-
ity among grade 2 lesions may be explained on the same
basis. However, we do see the expected inverse relation-
ship between hormone receptor positivity and HER-2/neu
positivity [60], which is highly significant for progester-
one receptor, which tends to validate our HER-2/neu scor-
ing.
Adjuvant therapy parameters such as tamoxifen and radi-
otherapy, were also not associated with recurrence, and
interactions of these important variables with expression
of candidate biomarkers such as COX-2 and PPARγ can-
not be meaningfully explored. However, it is not surpris-
ing that neither the radiation, nor the tamoxifen benefit
seen in large randomized trials is recapitulated in this
small case-control study, where the use of radiotherapy
(65 vs. 61%) and tamoxifen (32 vs.32%) was equally fre-
quent among cases and controls. Since radiotherapy and
tamoxifen exposure were not parameters under study in
this case-control design, this balance between cases and
controls is an advantage in terms of examining the effects
of other parameters. Our rate of invasive recurrence was
somewhat lower than reported in large trials [48], not
unexpected with a single institution sample where the
majority of patients received radiotherapy, and consistent
with the proportion of invasive recurrences seen in the
radiotherapy arm of NSABP B-18 [61].
Another challenge was the missing data on approximately
30% of tissue cores from the tissue microarrays. We chose
to construct tissue microarrays rather than using whole
sections because of the greater efficiency of this approach,
in order to evaluate multiple biomarkers in this explora-
tory study. Our success in retaining target tissue through
multiple sections of the TMA blocks was approximately
70%, which compares favorably with other reports in the
literature regarding target retention in TMAs of pre-inva-
sive lesions [62-64]. The retention rate for pre-invasive
lesions of interest in these studies ranged from 52%[64] to
79% [63]; Yang et al noted that target retention for non-
invasive targets (DCIS and terminal duct lobular units)
remained at about 79% for the first 30 sections, and then
declined to 64% at section 40 and 52% at section 100. We
noted the same trend, with attrition of target retention as
the sectioning progressed through a TMA block. We used
a core size of 1.5 mm, and achieved a target retention rate
close to that of Yang et. al., who advocates a core size of 2
mm. Target retention was not related to lesion size, in
agreement with Yang et. al. [63]
We did not observe an effect on recurrence risk of the
additional markers that we tested (ER, PR, HER-2/neu,
cyclin D, p53, p21). This is consistent with findings from
two other studies of multiple biomarkers and recurrence
risk, which included several of the markers that we have
examined [58,60]. These authors found no significant
impact of ER, PR, or HER-2/neu expression on recurrence
risk in multivariate analyses, although Ringberg et. al. did
observe a significant relation between a biologic index
consisting of seven different markers and risk of DCIS
recurrence on women who did not receive breast irradia-
tion. In another study, absence of HER-4 expression was
found to be a predictor of recurrence risk [65]. However,
our biomarker findings are validated by the observation
of many of the expected inter-relations between various
biomarkers, as shown in Table 5. Proteins along the ER
axis were significantly correlated: ER with PR, cyclin D1
and p21; PR with p21, and inversely with HER2/neu; cyc-
lin D1 with p21. The lack of association of PPARγ with ER
or PR is likely related to the small number of PPARγ posi-BMC Cancer 2008, 8:36 http://www.biomedcentral.com/1471-2407/8/36
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tive lesions, since such associations have been reported in
invasive breast cancers [48]
Conclusion
These data suggest that overexpression of COX-2 in DCIS
lesions is a strong risk factor for local recurrence in the
conserved breast; and that PPARg expression may protect
against such recurrence. A larger study is needed to vali-
date our findings, which might require a multi-institu-
tional effort. If validated, both COX-2 expression and
PPARγ expression would provide additional important
prognostic information in DCIS where current tools to
predict recurrence are inadequate. Additionally, there is
the potential for both agents to be administered together
given the cross talk between the two markers. Lastly, given
that COX-2 and PPARγ are expressed in both invasive and
noninvasive breast cancer, it would be useful to study
COX-2 and PPARγ expression in atypical proliferations to
see if these biomarkers will improve risk estimation, and
in the hopes of identifying molecular targets for chemo-
prevention.
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